U.S. based Kronos Bio has announced that it has appointed Philip Gutry as its Chief Business Officer.

In this newly created role, Philip will drive the company’s business development, corporate strategy and alliance management to expand clinical opportunities and propel pipeline expansion.

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

Phil joined Kronos from Regeneron Pharmaceuticals, where served as Executive Director of Business Development and was responsible for driving the immuno-oncology (IO) business development strategy and collaborating with R&D to guide clinical development strategy. He received his M.B.A. from The Wharton School and an A.B. from Dartmouth College.

Norbert Bischofberger, President and Chief Executive Officer of Kronos said, “We are thrilled to welcome Phil to Kronos. As we embark on what we intend to be rapid growth, Phil’s proven expertise in biotechnology and depth of knowledge across industry pipelines will be critical to our partnering efforts. His network and decades of experience developing, investing in, and operating across various stages of companies will be immediately leveraged as we look for additional opportunities to accelerate Kronos’ growth.”

Commenting on the appointment Phil said, “There is tremendous potential for Kronos’ platform to rapidly identify novel treatments with a particular focus on recalcitrant targets. I am looking forward to working with the team and building new industry partnerships to fully realize this potential. The broader Kronos team has an unparalleled track record of clinical development execution and approvals of breakthrough therapies. We plan to leverage this experience to accelerate development of in-licensed programs as well as our internally developed molecules.”